Reasons for Investigators to Participate Industry Sponsored Clinical Trials

연구자가 스폰서 주도 임상 시험에 참여하는 이유

  • Received : 2011.01.17
  • Accepted : 2011.03.01
  • Published : 2011.06.30

Abstract

Background: It is getting more difficult to involve appropriate investigators in clinical trials. Knowing what investigators want from sponsor initiated clinical trials would help industry cooperate with investigators more efficiently. This study aims to describe the incentives for investigators choosing to participate or not and perform well in sponsored clinical trials. Methods: Investigators who have participated in GSK sponsored clinical trials were interviewed face-to-face or through e-mail using the standardized questionnaire. Investigators were asked to choose five items and determine the ranking or those five items Results: Questionnaires answered by 122 investigators were collected. The top three incentives were "Academic merit" (108, 88.5 %), "Expectation of treatment potentially helpful to patient" (101, 82.8 %), and "Access to new treatments" (92, 75.4 %). The disincentives and the factors affecting an investigator's performance were analyzed separately because of the different questionnaire between investigators for medicine and vaccine. Investigators for medicine choose as disincentives "Insufficient time" (43, 61.4 %), "Difficult protocol" (41, 58.6 %), and "Adverse event concerns" (41, 58.6 %). Vaccine investigators pointed out "Limited support staff" (41, 78.8 %), "Insufficient time" (40, 76.9 %), and "Difficult blood sampling" (333, 63.5 %) as disincentives. Factors adversely affecting an investigator's performance showed similar results to those of disincentives. Conclusion: Investigators focused on academic curiosity and patients and insufficient time mostly inhibits them from participating and performing clinical trials. Our results would help industry cooperate with investigators more efficiently, finally making companies perform clinical trials more effectively.

Keywords

References

  1. Karlberg JP, Yau HK. Magnifier subscriber survey - incentives for participation in industry Sponsored Clinical Trials. Clinical Trial Magnifier, January 2009;2(1):37-51.
  2. Lee SM, Bang JS, Kim YI, Kim KS, La HO. The present state and revitalization plan for clinical trials in the medical institutions: a comparison study to the year 2003. Kor J Clin Pharmacol The, 2008;16(2):101-110.
  3. Rendell JM, Merritt RK, Geddes J. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database Syst Rev, 2007;18(2):1-25.
  4. Karlberg JP. Industry sponsored clinical trials in South Korea. Clinical Trial Magnifier, 2008;1(9):179-194.
  5. Brandt S, Hartmann J, Hehner S. How to design a successful disease-management program. McKinsey Quarterly, 2010; https://www. mckinseyquarterly.com/How_to_design_a_ successful_disease-management_program_2685. Accessed 27 Dec, 2010.